US · Healthcare · Biotechnology
EPS came in at 2.80 against a street estimate of 1.76 — a beat of 59.1%.
Analysts rate Incyte Corporation a buy (11 buy, 15 hold, 1 sell out of 27) with an average price target of $122.96.
| Fund | Stake |
|---|---|
| Baker Bros Advisors LP | 15.17% |
| BlackRock Inc | 9.36% |
| Dodge & Cox | 6.04% |
| Vanguard Capital Management, LLC | 5.39% |
| State Street Corp | 4.76% |
| Vanguard Portfolio Management, LLC | 3.83% |
| AQR Capital Management LLC | 2.87% |
| Geode Capital Management, LLC | 2.32% |
| Document | Date |
|---|---|
| Quarterly report · Q2 2026 | 2026-07-28 |
| Results announced · Q3 2026 | 2026-07-28 |
| Company announcement · Q3 2026 | 2026-07-06 |
| Company announcement · Q2 2026 | 2026-06-22 |
| Shareholder vote results · Q2 2026 | 2026-06-09 |
| Proxy statement · Q4 2025 | 2026-04-28 |
| Quarterly report · Q1 2026 | 2026-04-28 |
| Annual report FY2025 | 2026-02-10 |
Readable in the app.
| Announcement | Date |
|---|---|
| Completed acquisition of Vega Therapeutics from Star Therapeutics Incyte Corporation completed its acquisition of Vega Therapeutics, Inc. (a subsidiary of Star Therapeutics LLC) on July 6, 2026. This acquisition expands Incyte's pipeline and therapeutic ca | 2026-07-06 |
| Entered into definitive agreement to acquire Vega Therapeutics Incyte Corporation announced on June 8, 2026, that it has agreed to acquire Vega Therapeutics, Inc., a subsidiary of Star Therapeutics, LLC, under a definitive agreement. This is a strategic | 2026-06-08 |
Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Incyte Corporation — free to start.
Google PlayApp StoreData updated 2026-08-05.